<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9660">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05693298</url>
  </required_header>
  <id_info>
    <org_study_id>EGDS HFNC</org_study_id>
    <nct_id>NCT05693298</nct_id>
  </id_info>
  <brief_title>High Flow Nasal Cannula in Patients Undergoing Gastroscopy</brief_title>
  <official_title>High-flow Nasal Cannula Oxygen Therapy for Outpatients Undergoing Gastroscopy: a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Magna Graecia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Magna Graecia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      During gastroscopy, the insertion of the fiberscope and gastric distension required to&#xD;
      perform the examination may induce modifications to respiratory mechanics, respiratory effort&#xD;
      and breathing pattern.&#xD;
&#xD;
      High-flow nasal cannula (HFNC) therapy is a mixed air-oxygen supply system able to deliver&#xD;
      heated humidified gas up to 60 L/min of flow rate, with an inspiratory oxygen fraction (FiO2)&#xD;
      ranging from 21% to 100%. Increasing evidence supports the use of HFNC in several clinical&#xD;
      conditions and settings. When compared to standard therapy (ST), HFNC results in enhanced gas&#xD;
      exchange and improved comfort.&#xD;
&#xD;
      No studies have yet assessed the benefits of HFNC versus ST during and after gastroscopy. We&#xD;
      designed this unblinded randomized controlled trial to assess whether HFNC, compared to ST,&#xD;
      improves oxygenation at the end of the procedure (primary endpoint). Additional endpoints&#xD;
      were: 1) the lowest peripheral saturation of oxygen (SpO2) and the number of oxygen&#xD;
      desaturations; 2) the changes of end-expiratory lung impedance and tidal impedance assessed&#xD;
      by Electrical Impedance Tomography (EIT); 3) the effects on diaphragm function assessed by&#xD;
      ultrasound (DUS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2023</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial blood gases at end of the procedure</measure>
    <time_frame>Through study completion, an average of 15 minutes</time_frame>
    <description>Arterial blood will be sample for gas analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory effort at end of the procedure</measure>
    <time_frame>Through study completion, an average of 15 minutes</time_frame>
    <description>The respiratory effort will be assessed through the ultrasonographic assessment of the diaphragm thickening fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory effort at baseline</measure>
    <time_frame>After 1 minute from study beginning</time_frame>
    <description>The respiratory effort will be assessed through the ultrasonographic assessment of the diaphragm thickening fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory effort at the beginning of the gastroscopy</measure>
    <time_frame>5 minutes before the beginning of the bronchial endoscopy, while receiving the assigned treatment</time_frame>
    <description>The respiratory effort will be assessed through the ultrasonographic assessment of the diaphragm thickening fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory effort after the gastroscopy</measure>
    <time_frame>After 10 minute from the end of the endoscopy</time_frame>
    <description>The respiratory effort will be assessed through the ultrasonographic assessment of the diaphragm thickening fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of end-expiratory lung impedance (dEELI) from baseline at the beginning of the gastroscopy</measure>
    <time_frame>5 minutes before the beginning of the endoscopy, while receiving the assigned treatment, compared to baseline</time_frame>
    <description>change from baseline, expressed in mL, of the end expiratory lung volume as assessed through electrical impedance tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of end-expiratory lung impedance (dEELI) from baseline at end of the procedure</measure>
    <time_frame>Through study completion, an average of 15 minutes</time_frame>
    <description>change from baseline, expressed in mL, of the end expiratory lung volume as assessed through electrical impedance tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of end-expiratory lung impedance (dEELI) from baseline after gastroscopy</measure>
    <time_frame>After 10 minute from the end of the endoscopy, compared to baseline</time_frame>
    <description>change from baseline, expressed in mL, of the end expiratory lung volume as assessed through electrical impedance tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood gases at baseline</measure>
    <time_frame>After 1 minute from study beginning</time_frame>
    <description>Arterial blood will be sample for gas analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Gastroscopy</condition>
  <arm_group>
    <arm_group_label>High Flow Nasal Cannula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>If peripheral oxygen saturation will be &lt; 95%, conventional oxygen therapy will be administered through common nasal cannula with a flow up to 6 Liters per minute</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Flow Nasal Cannula</intervention_name>
    <description>High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%</description>
    <arm_group_label>High Flow Nasal Cannula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional Oxygen Therapy</intervention_name>
    <description>Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%</description>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  outpatients with the indication to diagnostic gastroscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  life-threatening cardiac aritmia or acute miocardical infarction within 6 weeks&#xD;
&#xD;
          -  need for invasive or non invasive ventilation&#xD;
&#xD;
          -  presence of pneumothorax or pulmonary enphisema or bullae&#xD;
&#xD;
          -  recent (within 1 week) thoracic surgery&#xD;
&#xD;
          -  presence of chest burns&#xD;
&#xD;
          -  presence of tracheostomy&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  nasal or nasopharyngeal diseases&#xD;
&#xD;
          -  dementia&#xD;
&#xD;
          -  lack of consent or its withdrawal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Longhini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Magna Graecia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Longhini</last_name>
    <phone>+393475395967</phone>
    <email>longhini.federico@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AOU Mater Domini</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>January 12, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>January 12, 2023</last_update_submitted>
  <last_update_submitted_qc>January 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Magna Graecia</investigator_affiliation>
    <investigator_full_name>Federico Longhini</investigator_full_name>
    <investigator_title>Director of the Intensive Care and Anesthesia Department</investigator_title>
  </responsible_party>
  <keyword>Gastroscopy</keyword>
  <keyword>High Flow Nasal Cannula</keyword>
  <keyword>Gas exchange</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The full protocol, datasets used and analysed during the current study will be available on reasonable request e-mailing the corresponding author</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data will be shared after results publication of indexed journal in english language</ipd_time_frame>
    <ipd_access_criteria>On reasonable request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

